Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Atara Biotherapeutics, Inc.

Ticker
ATRA
Sector
Industry
Report date
November 11, 2026
Valye AI Score

96

Very high visibility
Recent developments
Recent developments summary

Recent developments include Atara’s resubmission of the BLA for tabelecleucel to the FDA and ongoing regulatory activities. The company has reduced expenses following manufacturing transfer and workforce reductions. Liquidity remains supported by cash and investments, and equity offerings continue to provide capital.

Recent developments:
  • Atara resubmitted the Biologics License Application (BLA) for tabelecleucel to the FDA on September 30, 2026, continuing its regulatory efforts for product approval.[N1]
  • The company’s commercialization revenues have decreased significantly following the transfer of manufacturing responsibilities to Pierre Fabre in March 2025, with current revenues primarily from regulatory activities and clinical vial sales.[S2]
  • Research and development expenses decreased in 2026 compared to 2025 due to reduced headcount, transition of clinical trials to Pierre Fabre, and pausing of CAR T asset development.[S2]
  • General and administrative expenses also declined in 2026 following workforce reductions in 2025.[S2]
  • As of September 30, 2026, Atara held approximately $283.9 million in cash, cash equivalents, and short-term investments, with a current ratio of 1.72 and a cash ratio of 43.22, indicating liquidity.[S2]
  • The company continues to incur losses and negative cash flows and relies on equity offerings, including an ATM facility, to fund operations.[S2]
Overview

Atara Biotherapeutics, Inc. develops T-cell immunotherapies targeting diseases associated with Epstein-Barr Virus (EBV). Its lead product candidate, tabelecleucel (Tab-cel), is an off-the-shelf allogeneic EBV-specific T-cell immunotherapy intended for treatment of EBV-associated diseases. The company transferred manufacturing responsibilities for tabelecleucel to Pierre Fabre in March 2025, which now manages manufacturing and remediation costs related to FDA requests. Atara recognizes commercialization revenues primarily from regulatory activities and clinical vial sales, which have decreased following the manufacturing transfer. The company continues research and development activities, although it paused CAR T asset development and transitioned clinical trials to Pierre Fabre. Atara finances operations through equity offerings, including an ATM facility, and other arrangements. As of September 30, 2026, the company held approximately $283.9 million in cash, cash equivalents, and short-term investments, with liquidity ratios indicating adequate short-term financial resources. The company continues to incur losses and negative cash flows from operations.

Executive summary

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on T-cell immunotherapies, notably tabelecleucel (Tab-cel). The company transferred manufacturing responsibilities to Pierre Fabre in March 2025, which now handles manufacturing and remediation costs related to FDA requirements. Commercialization revenues have decreased significantly post-transfer, reflecting ongoing regulatory activities and clinical vial sales. The company reported a net loss of $2.2 million and EPS of -$0.15 for Q3 2026. Liquidity remains supported by cash, cash equivalents, and short-term investments totaling approximately $283.9 million as of September 30, 2026, with a current ratio of 1.72 and a cash ratio of 43.22. Atara continues to incur losses and negative cash flows and relies on equity offerings and other financing arrangements to fund operations. The company recently resubmitted the BLA for tabelecleucel to the FDA and is engaged in regulatory activities to advance commercialization. Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.[S2]

Scenarios for ATRA

Bull case model:

Atara’s recent resubmission of the BLA for tabelecleucel to the FDA represents a key regulatory milestone. The transfer of manufacturing responsibilities to Pierre Fabre reduces operational complexity and shifts remediation costs, potentially improving operational efficiency. The company’s liquidity position, supported by cash, cash equivalents, and short-term investments, provides resources to continue regulatory and clinical activities. Reduced expenses following workforce reductions and manufacturing transitions may improve financial flexibility. Strategic equity offerings and ATM facilities provide avenues for capital raising to support ongoing operations.

Bear case model:

Atara continues to incur losses and negative cash flows, reflecting the high costs of biopharmaceutical development and commercialization. The company’s revenues have decreased significantly following the transfer of manufacturing responsibilities, limiting near-term commercialization income. Regulatory approvals remain uncertain, and the company depends on additional capital raising, which may dilute existing shareholders. Limitations on sales under shelf registration statements due to public float constraints may restrict financing flexibility. Operational risks include successful regulatory submissions, manufacturing transitions, and maintaining sufficient liquidity to fund ongoing activities.

Moat:

Atara Biotherapeutics’ moat is based on its proprietary T-cell immunotherapy platform targeting EBV-associated diseases, with tabelecleucel as a lead candidate. The company’s strategic partnership with Pierre Fabre for manufacturing and commercialization leverages external expertise and resources, potentially accelerating product development and market access. The specialized nature of its immunotherapy products and regulatory approvals required create barriers to entry for competitors. However, the company faces risks related to regulatory approvals, manufacturing transitions, and capital requirements inherent in biopharmaceutical development.

Risks overview
Risks summary
The primary risk for Atara Biotherapeutics is the uncertainty surrounding regulatory approval of its lead product candidate and the need for ongoing capital to sustain operations.
Risks details:

• Regulatory Approval Risk: The company’s ability to commercialize tabelecleucel depends on successful FDA approval of the BLA, which remains uncertain despite recent resubmission.
• Capital Raising and Dilution Risk: Atara has incurred losses and negative cash flows since inception and requires additional capital, which may result in dilution of existing shareholders.
• Manufacturing and Supply Risk: Transition of manufacturing to Pierre Fabre introduces dependency on a third party for production and remediation activities, which may affect supply continuity.
• Operational and Execution Risk: Reduced headcount and paused development programs may impact the company’s ability to execute research, development, and commercialization plans effectively.

FINAL FORECAST FOR ATRA

Final take one line
Atara Biotherapeutics has clear visibility into its regulatory and operational status with recent BLA resubmission and ongoing capital management amid continued losses.
Final take 12 to 24 month view

Business trends: Continued focus on regulatory approval of tabelecleucel and transition of manufacturing to Pierre Fabre, with reduced commercialization revenues.
Execution milestones: Resubmission of BLA to FDA, management of manufacturing partnership, and capital raising through equity offerings and ATM facility.
Key risks: Regulatory approval uncertainty, ongoing capital requirements with dilution risk, dependency on third-party manufacturing, and operational execution challenges due to workforce reductions.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

96
LLM visibility overview
LLM Visibility known facts
  • Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel T-cell immunotherapies.
  • The company’s lead product candidate is tabelecleucel (Tab-cel), an off-the-shelf allogeneic EBV-specific T-cell immunotherapy.
  • Atara transferred all manufacturing responsibilities for tabelecleucel to Pierre Fabre as of March 31, 2025, with Pierre Fabre responsible for manufacturing and supplying the product worldwide under an amended commercialization agreement.
  • Pierre Fabre also assumed costs related to remediation of a third-party manufacturing facility to support FDA requests for the BLA resubmission for tabelecleucel.
  • Atara recognizes commercialization revenues primarily from ongoing regulatory activities and clinical vial sales, which were $1.2 million for the three months ended September 30, 2026, significantly lower than prior periods due to the manufacturing transfer.
  • The company incurred a net loss of $2.2 million for the three months ended September 30, 2026, with an EPS of -$0.15.
  • Research and development expenses decreased in 2026 compared to 2025, reflecting reduced headcount, transition of clinical trials to Pierre Fabre, and pausing of CAR T asset development.
  • General and administrative expenses also decreased due to reduced headcount following 2025 workforce reductions.
  • Atara has a 2023 ATM Facility allowing sales of common stock up to $100 million, with $78.3 million remaining as of September 30, 2026.
  • The company intends to file a new shelf registration statement (2026 Registration Statement) to replace the 2023 Registration Statement before its expiration on November 13, 2026.
  • Atara’s cash, cash equivalents, and short-term investments totaled approximately $283.9 million as of September 30, 2026, with a current ratio of 1.72 and a cash ratio of 43.22, indicating liquidity.
  • The company has incurred losses and negative cash flows since inception and continues to require additional capital to fund operations.
  • Atara’s regulatory strategy includes resubmission of the BLA for tabelecleucel to the FDA, with recent resubmission reported on September 30, 2026.
  • The company’s revenues and expenses reflect the transition of manufacturing and clinical activities to Pierre Fabre and workforce reductions in 2025.
  • Atara’s commercialization revenues and costs have significantly decreased following the transfer of manufacturing responsibilities.
  • The company’s financial disclosure states that figures are summarized from the latest SEC filings and provided for informational purposes only.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-16 | 10-K
  • S2 | 2026-11-10 | 10-Q
Sources - News headlines
  • N1 | 2026-09-30 | www.nasdaq.com | Atara Resubmits Tabelecleucel BLA To FDA | https://www.nasdaq.com/articles/atara-resubmits-tabelecleucel-bla-fda
  • N2 | 2026-09-08 | www.nasdaq.com | 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara | https://www.nasdaq.com/articles/5-biotech-stocks-watch-bluejay-pharvaris-roivant-pdsb-atara
  • N3 | 2026-09-08 | www.nasdaq.com | ISpecimen In Focus, Genelux Nears Phase 3 Ovarian Cancer Data, Biofrontera Awaits FDA Decision | https://www.nasdaq.com/articles/ispecimen-focus-genelux-nears-phase-3-ovarian-cancer-data-biofrontera-awaits-fda-decision
  • N4 | 2026-06-30 | www.nasdaq.com | Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement | https://www.nasdaq.com/articles/tenaya-therapeutics-names-eric-hyllengren-cfo-ahead-higa-retirement
  • N5 | 2026-05-08 | www.nasdaq.com | Weekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI | https://www.nasdaq.com/articles/weekly-buzz-fda-clears-tab-cel-path-arvinas-wins-protac-nod-novartis-cuts-jobs-roche-buys
  • N6 | 2026-01-12 | www.nasdaq.com | Monday Sector Laggards: Biotechnology, Credit Services & Lending Stocks | https://www.nasdaq.com/articles/monday-sector-laggards-biotechnology-credit-services-lending-stocks
  • N7 | 2025-12-20 | www.nasdaq.com | Canaccord Genuity Maintains Atara Biotherapeutics (ATRA) Buy Recommendation | https://www.nasdaq.com/articles/canaccord-genuity-maintains-atara-biotherapeutics-atra-buy-recommendation
  • N8 | 2025-11-10 | www.nasdaq.com | Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/wave-life-sciences-wve-reports-q3-loss-misses-revenue-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine